GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » Scaled Net Operating Assets

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Scaled Net Operating Assets : 0.69 (As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Shenzhenlubris Pharmaceuticals Co's operating assets for the quarter that ended in Dec. 2024 was ¥8,606 Mil. Shenzhenlubris Pharmaceuticals Co's operating liabilities for the quarter that ended in Dec. 2024 was ¥1,579 Mil. Shenzhenlubris Pharmaceuticals Co's Total Assets for the quarter that ended in Sep. 2024 was ¥10,233 Mil. Therefore, Shenzhenlubris Pharmaceuticals Co's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2024 was 0.69.


Shenzhenlubris Pharmaceuticals Co Scaled Net Operating Assets Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co Scaled Net Operating Assets Chart

Shenzhenlubris Pharmaceuticals Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.70 0.56 0.68 0.75

Shenzhenlubris Pharmaceuticals Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.71 0.67 0.73 0.69

Competitive Comparison of Shenzhenlubris Pharmaceuticals Co's Scaled Net Operating Assets

For the Medical Instruments & Supplies subindustry, Shenzhenlubris Pharmaceuticals Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhenlubris Pharmaceuticals Co's Scaled Net Operating Assets Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shenzhenlubris Pharmaceuticals Co's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Shenzhenlubris Pharmaceuticals Co's Scaled Net Operating Assets falls into.


;
;

Shenzhenlubris Pharmaceuticals Co Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Shenzhenlubris Pharmaceuticals Co's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2024 )
=(Operating Assets (A: Dec. 2024 )-Operating Liabilities (A: Dec. 2024 ))/Total Assets (A: Dec. 2023 )
=(8606.335-1579.408)/9396.673
=0.75

where

Operating Assets(A: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=10465.604 - 1859.269
=8606.335

Operating Liabilities(A: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1713.287 - 4.175 - 129.704
=1579.408

Shenzhenlubris Pharmaceuticals Co's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2024 )
=(Operating Assets (Q: Dec. 2024 )-Operating Liabilities (Q: Dec. 2024 ))/Total Assets (Q: Sep. 2024 )
=(8606.335-1579.408)/10232.539
=0.69

where

Operating Assets(Q: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=10465.604 - 1859.269
=8606.335

Operating Liabilities(Q: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1713.287 - 4.175 - 129.704
=1579.408

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shenzhenlubris Pharmaceuticals Co Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhenlubris Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No. 6009 Shennan Road, 37th Floor, Main Building, Chegongmiao Lvjing Plaza, Futian District, Guangdong, Shenzhen, CHN, 518040
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.
Executives
Yan Jie Directors, executives
Yang Jian Feng Secretary, Director
Zhao Song Ping Executives
Liu Jun Executives
Li Ai Zhen Supervisors
Chen Ping Executives
Ye Cheng Hai Director
Lu Feng Executives, directors
Chen Qiong Xing Supervisors
Li Ying Hui Supervisors
Pan Ling Man Independent director
Zhang Zhong Xing Executives

Shenzhenlubris Pharmaceuticals Co Headlines

No Headlines